C 1027

07/14/2005 - "Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule."
12/01/2017 - "In the present study, the effect of lidamycin (LDM) on CD133 expression in hepatocellular carcinoma (Huh7 cells) was evaluated and the potential molecular mechanism was investigated. "
01/01/2015 - "In this study, we evaluated the effect of lidamycin on tumor initiating cells of hepatocellular carcinoma Huh7 and identified the potential mechanism. "
07/14/2005 - "To study the in vitro and in vivo antitumor effect of lidamycin (LDM) on hepatoma and the active moiety of its molecule. "
09/15/2004 - "The aim of this study was to investigate the possible link between centrosome dynamics and lidamycin-induced mitotic cell death in human hepatoma BEL-7402 cells. "

01/01/2015 - "Transarterial oily chemoembolization with lidamycin shows potent therapeutic efficacy in VX2 rabbit liver tumor."
11/01/2011 - "This study is to investigate inhibitory effects of lidamycin (LDM) on the proliferation of HERG K+ channel highly expressing cancer cells and its synergy with anticancer drugs. "
12/20/2016 - "We confirmed one clade as new C-1027 producers, with a significantly higher C-1027 titer than the original producer, and discovered a new family of enediyne natural products, the tiancimycins (TNMs), that exhibit potent cytotoxicity against a broad spectrum of cancer cell lines. "
01/01/2015 - "In addition, lidamycin restrained tumor volume and incidence in vivo. "
01/01/2015 - "Subcutaneous tumor model in nude mice was used to observe in vivo effect of lidamycin on Huh7 cells. "

01/01/2016 - "The aim of this study is to explore the antitumor efficacy of lidamycin (LDM) against human multiple myelomas (MM). "
07/01/2013 - "Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells."
01/01/2016 - "Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice."
07/01/2009 - "In the present study, the effects of lidamycin (LDM), a member of the enediyne antibiotic family, on two human multiple myeloma (MM) cell lines, U266 and SKO-007, were evaluated. "
07/01/2009 - "To investigate the effects of lidamycin (LDM) on a mouse myeloma cell line (SP2/0) and human multiple myeloma cell lines (U266 and SKO-007), and provide the basis for the use of LDM in cancer therapy. "

05/01/2008 - "To investigate the effects on human pancreatic cancer PANC-1 and SW1990 cells using a combination of lidamycin (LDM) and gemcitabine. "
06/01/2007 - "Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth."
01/01/2019 - "We generated a dual-targeting ligand-based lidamycin (DTLL) to investigate its efficacy against pancreatic cancer after preparing its precursor, DTLP. "
05/01/2008 - "Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells."
09/04/2012 - "We first developed a highly sensitive method for characterization of DNA fragments using a home-built FCS system and SYBR Green I as fluorescent DNA-intercalating dye, and then established a model of drug-induced apoptosis using human pancreatic cancer cells and a drug lidamycin. "

07/07/2009 - "Conclusion Lidamycin can inhibit vasculogenic mimicry and promote apoptosis of glioma cells. "
07/07/2009 - "Tube formation assay was performed to estimate the inhibitory effects of lidamycin upon vasculogenic mimicry in C6 and U87 glioma cells. "
07/07/2009 - "To evaluate the in vitro effects of lidamycin upon vasculogenic mimicry and apoptosis induction in glioma cells. "
07/07/2009 - "[Inhibitory effect of lidamycin upon vasculogenic mimicry and its induction of apoptosis in glioma cells]."
11/20/2012 - "Furthermore, in the glioma U87 xenograft model in nude mice, (Arg)(9)-LDP-AE at 0.2mg/kg suppressed tumor growth by 88.8%, compared with that of lidamycin by 62.9% at 0.05 mg/kg. No obvious toxic effects were observed in all groups during treatments. "